13F-HR filed by Remedium Capital Partners, LLC
Remedium Capital Partners, LLC filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-12, with 6 holding rows worth $170,211,000.
- Accession
- 0002104501-26-000004
- Filer
- CIK 2104501
- Filed
- 2026-02-12
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 6 entries on the cover page, a total value of $170,211,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $170,211,000 with VALUE read as thousands, detected and multiplied, 13F file number 028-26277. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 1,456,231 | $47,706,000 | thousands, detected and multiplied | |
| ORUKA THERAPEUTICS INC COM | 687604108 | Stock | 1,552,414 | $47,054,000 | thousands, detected and multiplied | |
| APOGEE THERAPEUTICS INC COM | 03770N101 | Stock | 583,591 | $44,050,000 | thousands, detected and multiplied | |
| JADE BIOSCIENCES INC | 008064206 | COM NEW | 1,577,750 | $24,345,000 | thousands, detected and multiplied | |
| CRESCENT BIOPHARMA INC. | 38000Q201 | COM | 361,250 | $4,284,000 | thousands, detected and multiplied | |
| DAMORA THERAPEUTICS INC | 36322Q206 | COMMON STOCK | 120,473 | $2,772,000 | thousands, detected and multiplied |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0002104501-26-000004 | this filing | 2026-02-12 | acceptance time not in the bulk data set |